BTS
PRVB

BB&T Securities’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

BB&T Securities’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$136K Buy
+20,000
New +$202K ﹤0.01% 1553

Other funds holding PRVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SCM
Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

BB&T Securities's PRVB Position: Q3 2019 in Review

BB&T Securities opened a new position in Provention Bio, Inc. Common Stock (PRVB) in Q3 2019: 20,000 shares worth $136K. The stake represents ﹤0.01% of the portfolio and ranks #1553 among its holdings.

48 funds tracked by Wall St. Rank hold PRVB as of Q3 2019.

  • BB&T Securities held 20,000 shares of Provention Bio, Inc. Common Stock worth $136K as of Q3 2019.
  • Provention Bio, Inc. Common Stock was a new BB&T Securities position in Q3 2019.
  • Provention Bio, Inc. Common Stock made up ﹤0.01% of BB&T Securities's portfolio in Q3 2019, its #1553 holding.
  • 48 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q3 2019.

Based on BB&T Securities's 13F filing for Q3 2019, filed 30 Oct 2019.